ACOG Practice Bulletin no. 92: Use of psychiatric medications during pregnancy and lactation

Obstetrics and Gynecology

Volumn 111, Issue 4, 2008, Pages 1001-1020

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMOXAPINE; BUSPIRONE; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; DESIPRAMINE; DIAZEPAM; DOXEPIN; ESTAZOLAM; ESZOPICLONE; ESZOPLICONE; FLURAZEPAM; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; LORAZEPAM; MAPROTILINE; NORTRIPTYLINE; OXAZEPAM; QUAZEPAM; SERTRALINE; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ANEMIA; ANXIETY DISORDER; BIPOLAR DISORDER; BLOOD CLOTTING DISORDER; BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CHOLESTATIC HEPATITIS; CLEFT FACE; CRANIOFACIAL MALFORMATION; CYANOSIS; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EBSTEIN ANOMALY; ELECTROCARDIOGRAM; ELECTROCONVULSIVE THERAPY; FACE DYSMORPHIA; FLACCID PARALYSIS; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYDRAMNIOS; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; HYPOPLASIA; HYPOTHERMIA; INFANTILE HYPOTONIA; INSOMNIA; LACTATION; LETHARGY; LIMB MALFORMATION; LIVER TOXICITY; MAJOR DEPRESSION; MEDICAL DOCUMENTATION; MUSCLE HYPOTONIA; NEPHROGENIC DIABETES INSIPIDUS; NEURAL TUBE DEFECT; OBSESSIVE COMPULSIVE DISORDER; OMPHALOCELE; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL PHOBIA; THERAPY EFFECT; THROMBOCYTOPENIA; THYROID FUNCTION; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; BREAST FEEDING; CARBAMAZEPINE; DEPRESSION; FEMALE; FETUS; HUMANS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK ASSESSMENT; SAFETY; SCHIZOPHRENIA; VALPROIC ACID;

EID: 41649107792     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31816fd910     Document Type: Review

References (245)

1. Doering PL, Stewart RB. The extent and character of drug consumption during pregnancy. JAMA 1978;239:843-6. (Level III)
2. Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry 2000;48(10):1032-4. (Level III)
3. Newport DJ, Hostetter A, Arnold A, Stowe ZN. The treatment of postpartum depression: minimizing infant exposures. J Clin Psychiatry. 2002;63 (Suppl 7):31-44. (Level III)
4. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19. (Level II-3)
5. National Institute of Mental Health (US). The numbers count: mental disorders in America. NIH Publication No. 06-4584. Bethesda (MD): NIMH; 2006. Available at: http://www.nimh.nih.gov/publicat/numbers.cfm. Retrieved December 12, 2006. (Level II-3)
6. Weissman M, Olfson M. Depression in women: implications for health care research. Science 1995;269:799-801. (Level III)
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR 4th ed. text version. Washington, DC: APA; 2000. (Level III)
8. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course and predictive factors. J Abnorm Psychol 1984;93:158-71. (Level II-3)
9. Gotlib IH, Whiffen VE, Mount JH, Milne K, Cordy NI. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989;57:269-74. (Level III)
10. Affonso DD, Lovett S, Paul SM, Sheptak S. A standardized interview that differentiates pregnancy and postpartum symptoms from perinatal clinical depression. Birth 1990;17:121-30. (Level II-3)
11. Kumar R, Robson K. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984;144:35-47. (Level II-3)
12. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000;11:51-7. (Level III-3)
13. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment [published erratum appears in JAMA 2006;296:170]. JAMA 2006;295:499-507. (Level II-2)
14. Cox J. Postnatal mental disorder: towards ICD-11. World Psychiatry 2004;3:96-7. (Level III)
15. Stowe ZN, Hostetter AL, Newport DJ. The onset of post-partum depression: implications for clinical screening in obstetrical and primary care. Am J Obstet Gynecol 2005;192:522-6. (Level II-3)
16. Watson JP, Elliott SA, Rugg AJ, Brough DI. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 1984;144:453-62. (Level II-3)
17. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001;323:257-60. (Level II-2)
18. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987;150:782-6. (Level III)
19. Murray L, Carothers AD. The validation of the Edinburgh Post-natal Depression Scale on a community sample. Br J Psychiatry 1990;157:288-90. (Level III)
20. Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000;19:535-43. (Level II-2)
21. Field T, Diego MA, Dieter J, Hernandez-Reif M, Schanberg S, Kuhn C, et al. Depressed withdrawn and intrusive mothers' effects on their fetuses and neonates. Infant Behav Dev 2001;24:27-39. (Level II-2)
22. Zuckerman B, Bauchner H, Parker S, Cabral H. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990;11:190-4. (Level II-3)
23. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989;160:1107-11. (Level II-2)
24. Zuckerman B, Frank DA, Hingson R, Amaro H, Levenson SM, Kayne H, et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989;320:762-8. (Level II-3)
25. Rosett HL, Weiner L, Lee A, Zuckerman B, Dooling E, Oppenheimer E. Patterns of alcohol consumption and fetal development. Obstet Gynecol 1983;61:539-46. (Level II-2)
26. Sexton M, Hebel JR. A clinical trial of change in maternal smoking and its effect on birth weight. JAMA 1984;251:911-5. (Level I)
27. Weissman MM, Prusoff BA, Gammon GD, Merikangas KR, Leckman JF, Kidd KK. Psychopathology in the children (ages 6-18) of depressed and normal parents. J Am Acad Child Psychiatry 1984;23:78-84. (Level II-2)
28. Lyons-Ruth K, Wolfe R, Lyubchik A. Depression and the parenting of young children: making the case for early preventive mental health services. Harv Rev Psychiatry 2000;8:148-53. (Level III)
29. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-31. (Level II-3)
30. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published erratum appears in Arch Gen Psychiatry 2005;62:709]. Arch Gen Psychiatry 2005;62:617-627. (Level II-3)
31. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-58. (Level II-3)
32. Angst J. The course of affective disorders. II. Typology of bipolar manic-depressive illness. Arch Psychiatr Nervenkr 1978;226:65-73. (Level III)
33. Yildiz A, Sachs GS. Characteristics of rapid cycling bipolar-I patients in a bipolar specialty clinic. J Affect Disord 2004;79:247-51. (Level II-3)
34. McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI, Faedda GL, Swan AC. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992;149:1633-44. (Level III)
35. Arnold LM, McElroy SL, Keck PE Jr. The role of gender in mixed mania. Compr Psychiatry 2000;41:83-7. (Level III)
36. Akdeniz F, Vahip S, Pirildar S, Vahip I, Doganer I, Bulut I. Risk factors associated with childbearing-related episodes in women with bipolar disorder. Psychopathology 2003;36:234-8. (Level II-3)
37. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002;63:284-7. (Level III)
38. Grof P, Robbins W, Alda M, Berghoefer A, Vojtechovsky M, Nilsson A, et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000;61:31-9. (Level III)
39. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-84. (Level II-2)
40. Kendall RE, Chalmers JC, Platz C. Epidemiology of puerperal psychosis [published erratum appears in Br J Psychiatry 1987;151:135]. Br J Psychiatry 1987;150:662-673. (Level II-2)
41. Marks MN, Wieck A, Checkley SA, Kumar R. Contribution of psychological and social factors to psychotic and non-psychotic relapse after childbirth in women with previous histories of affective disorder. J Affect Disord 1992;24:253-63. (Level II-2)
42. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication [published erratum appears in Arch Gen Psychiatry 2005;62:768]. Arch Gen Psychiatry 2005;62:593-602. (Level II-3)
43. Boyles SH, Ness RB, Grisso JA, Markovic N, Bromberger J, CiFelli D. Life event stress and the association with spontaneous abortion in gravid women at an urban emergency department. Health Psychol 2000;19:510-4. (Level II-2)
44. Berkowitz GS, Kasl SV. The role of psychosocial factors in spontaneous preterm delivery. J Psychosom Res 1983;27:283-90. (Level II-2)
45. Perkin MR, Bland JM, Peacock JL, Anderson HR. The effect of anxiety and depression during pregnancy on obstetric complications. Br J Obstet Gynaecol 1993;100:629-34. (Level II-2)
46. Pagel MD, Smilkstein G, Regen H, Montano D. Psychosocial influences on new born outcomes: a controlled prospective study. Soc Sci Med 1990;30:597-604. (Level II-2)
47. Taylor A, Fisk NM, Glover V. Mode of delivery and subsequent stress response. Lancet 2000;355:120. (Level II-2)
48. Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994;55:539-42. (Level III)
49. Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. Postpartum course in women with preexisting panic disorder. J Clin Psychiatry 1994;55:289-92. (Level III)
50. Loveland Cook CA, Flick LH, Homan SM, Campbell C, McSweeney M, Gallagher ME. Posttraumatic stress disorder during pregnancy: prevalence, risk factors, and treatment. Obstet Gynecol 2004;103:710-7. (Level II-3)
51. Neziroglu F, Anemone R, Yaryura-Tobias JA. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992;149:947-50. (Level III)
52. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20:399-403. (Level III)
53. Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br J Psychiatry 1999;175:239-45. (Level II-2)
54. Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res 2002;58:221-9. (Level II-2)
55. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005;162(1):79-91. (Level II-2)
56. Bennedsen BE, Mortensen PB, Olesen AV, Henriksen TB, Frydenberg M. Obstetric complications in women with schizophrenia. Schizophr Res 2001;47:167-75. (Level II-2)
57. Coons PM, Ascher-Svanum H, Bellis K. Self-amputation of the female breast. Psychosomatics 1986;27:667-8. (Level III)
58. Yoldas Z, Iscan A, Yoldas T, Ermete L, Akyurek C. A woman who did her own caesarean section. Lancet 1996;348:135. (Level III)
59. Slayton RI, Soloff PH. Psychotic denial of third-trimester pregnancy. J Clin Psychiatry 1981;42:471-3. (Level III)
60. Bucove AD. A case of prepartum psychosis and infanticide. Psychiatr Q 1968;42:263-70. (Level III)
61. Mendlowicz MV, da Silva Filho JF, Gekker M, de Moraes TM, Rapaport MH, Jean-Louis F. Mothers murdering their newborns in the hospital. Gen Hosp Psychiatry 2000;22:53-5. (Level III)
62. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-6. (Level II-2)
63. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96. (Level II-2)
64. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7. (Meta-analysis)
65. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM 2007;356:2675-83. (Level II-2)
66. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. National Birth Defects Prevention Study. NEJM 2007;356:2684-92. (Level II-2)
67. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83. (Level III)
68. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-15. (Level II-2)
69. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32. (Level II-2)
70. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-316. (Level II-2)
71. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-75. (Level II-2)
72. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Level II-2)
73. Barson AJ. Malformed infant. Br Med J 1972;2:45. (Level III)
74. Elia J, Katz IR, Simpson GM. Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 1987;23:531-86. (Level III)
75. McBride WG. Limb deformities associated with iminodibenzyl hydrochloride. Med J Austr 1972;1:492. (Level III)
76. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606. (Level III)
77. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94. (Level III)
78. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JA et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62. (Level II-2)
79. Prentice A, Brown R. Fetal tachyarrhythmia and maternal antidepressant treatment. BMJ 1989;298:190. (Level III)
80. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973;2:680. (Level III)
81. Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 1991;9:275-98. (Level III)
82. Webster PA. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-9. (Level III)
83. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991;21:157-71. (Level II-3)
84. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-61. (Level II-2)
85. Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E, Kalyoncu NI, et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235-8. (Level II-3)
86. Yaris F, Ulku C, Kesim M, Kadioglu M, Unsal M, Dikici MF, et al. Psychotropic drugs in pregnancy: a case-control study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:333-8. (Level II-2)
87. Kesim M, Yaris F, Kadioglu M, Yaris E, Kalyoncu NI, Ulku C. Mirtazapine use in two pregnant women: is it safe? Teratology 2002;66:204. (Level III)
88. Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003;268:219-21. (Level III)
89. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-10. (Level II-2)
90. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932-6. (Level II-2)
91. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-50. (Level III)
92. Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001;46:710-9. (Level III)
93. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein's anomaly, and other congenital heart defects [letter]. Lancet 1974;2:594-5. (Level III)
94. Weinstein MR, Goldfield M. Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 1975;132:529-31. (Level III)
95. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium [published erratum appears in JAMA 1994;271:1485]. JAMA 1994;271:146-50. (Level III)
96. Kallen B, Tandberg A. Lithium and pregnancy. A cohort of manic-depressive women. Acta Psychiatr Scand 1983;68:134-9. (Level II-2)
97. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-3. (Level II-2)
98. Friedman JM, Polifka JE. Teratogenic effects of drugs: a resource for clinicians (TERIS). 2nd ed. Baltimore (MD): Johns Hopkins University Press; 2000. (Level III)
99. Wilson N, Forfar JC, Godman MJ. Atrial flutter in the newborn resulting from maternal lithium ingestion. Arch Dis Child 1983;58:538-9. (Level III)
100. Mizrahi EM, Hobbs JF, Goldsmith DI. Nephrogenic diabetes insipidus in transplacental lithium intoxication. J Pediatr 1979;94:493-5. (Level III)
101. Karlsson K, Lindstedt G, Lundberg PA, Selstam U. Transplacental lithium poisoning: reversible inhibition of fetal thyroid [letter]. Lancet 1975;1:1295. (Level III)
102. Llewellyn A, Stowe ZN, Strader JR Jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998;59(suppl 6):57-64;discussion 65. (Level III)
103. Woody JN, London WL, Wilbanks GD Jr. Lithium toxicity in a newborn. Pediatrics 1971;47:94-6. (Level III)
104. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976;54:193-7. (Level II-2)
105. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-8. (Level 11-2)
106. Jager-Roman E, Deichl A, Jakob S, Hartmann AM, Koch S, Rating D, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108:997-1004. (Level II-2)
107. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-3. (Level III-3)
108. Spina bifida incidence at birth - United States, 1983-1990. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep 1992;41:497-500. (Level II-3)
109. Samren E, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-90. (Level II-2)
110. Omtzigt JG, Los FJ, Meiger JW, Lindhout D. The 10, 11-epoxide-10, 11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. Ther Drug Monit 1993;15:1-10. (Level II-3)
111. Samren E, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46. (Level II-2)
112. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-6. (Level II-2)
113. Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58. (Level II-2)
114. Paulson GW, Paulson RB. Teratogenic effects of anticonvulsants. Arch Neurol 1981;38:140-3. (Level III)
115. Rodriguez-Pinilla E, Arroyo I, Fondevilla J, Garcia MJ, Martinez-Frias ML. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000;90:376-81. (Level II-2)
116. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980:97:332-3. (Level III)
117. Koch S, Jager-Roman E, Rating D, Helge H. Possible teratogenic effect of valproate during pregnancy. J Pediatr 1983;103:1007-8. (Level III)
118. Sodhi P, Poddar B, Parmar V. Fatal cardiac malformation in fetal valproate syndrome. Indian J Pediatr 2001;68:989-90. (Level III)
119. Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987;24:692-5. (Level III)
120. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-85. (Level III)
121. Martinez-Frias ML. Clinical manifestation of prenatal exposure to valproic acid using case reports and epidemiologic information. Am J Med Genet 1990;37:277-82. (Level III)
122. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98:168-75. (Level III)
123. Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997;39:632-4. (Level III)
124. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000;37:489-97. (Level III)
125. Bescoby-Chambers N, Forster P, Bates G. Foetal valproate syndrome and autism: additional evidence of an association [letter]. Dev Med Child Neurol 2001;43:847. (Level III)
126. Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001;43:202-6. (Level III)
127. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990;32:403-14. (Level II-2)
128. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21. (Level II-2)
129. Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 1998;23:223-8. (Level III)
130. Mountain KR, Hirsch J, Gallus AS. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1970;1:265-8. (Level II-3)
131. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993;69:288-91. (Level III)
132. Ebbesen F, Joergensen A, Hoseth E, Kaad PH, Moeller M, Holsteen V, et al. Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. Arch Dis Child Fetal Neonatal Ed 2000;83:F124-9. (Level II-2)
133. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-6. (Level II-3)
134. Scolnik D, Nulman I, Rovet J, Gladstone D, Czuchta D, Gardner HA, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy [published erratum appears in JAMA 1994;271:1745]. JAMA 1994;271:767-70. (Level II-2)
135. Wide K, Winbladh B, Tomson T, Sars-Zimmer K, Berggren E. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study [published erratum appears in Dev Med Child Neurol 2000;42:356]. Dev Med Child Neurol 2000;42:87-92. (Level II-2)
136. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996;75:517-20. (Level II-2)
137. Gaily E, Granstrom ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res. 1998;42 (suppl 1):41-5. (Level III)
138. Van der Pol MC, Hadders-Algra M, Huisjes MJ, Touwen BC. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991;164:121-8. (Level II-2)
139. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17. (Meta-analysis)
140. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003;10:543-9. (Level II-2)
141. Sabers A, Dam M, A-Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109:9-13. (Level III)
142. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Neurology 2005;64:955-60. (Level III)
143. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 2004;45:1465. (Level III)
144. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, et al. In utero antiepileptic drug exposure: fetal death and malformations. NEAD Study Group. Neurology 2006;67:407-12. (Level II-2)
145. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8. (Level II-2)
146. Baldessarini RJ, Faedda GL, Hennen J. Risk of mania with antidepressants. Arch Pediatr Adolesc Med 2005;159:298. (Level III)
147. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005;162:2162-70. (Level III)
148. Choulika S, Grabowski E, Holmes LB. Is antenatal vitamin K prophylaxis needed for pregnant women taking anticonvulsants? Am J Obstet Gynecol 2004;190:882-3. (Level II-2)
149. Saxen I. Cleft palate and maternal diphenhydramine intake [letter]. Lancet 1974;1:407-8. (Level III)
150. Aarkog D. Association between maternal intake of diazepam and oral clefts [letter]. The Lancet 1975;2:921. (Level II-2)
151. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975;4:37-44. (Level II-2)
152. Eros E, Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Euro J Obstet, Gynecol Reprod Biol 2002;101:147-54. (Level II-2)
153. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol 2004;70:534-6. (Level III-3)
154. Haram K. "Floppy infant syndrome" and maternal diazepam. Lancet 1977;2:612-3. (Level III)
155. Speight AN. Floppy-infant syndrome and maternal diazepam and/or nitrazepam. Lancet 1977;2:878. (Level III)
156. Woods DL, Malan AF. Side-effects of maternal diazepam on the newborn infant. S Afr Med J 1978;54:636. (Level III)
157. Kriel RL, Cloyd J. Clonazepam and pregnancy. Ann Neurol 1982;11:544. (Level III)
158. McAuley DM, O'Neill MP, Moore J, Dundee JW. Lorazepam premedication for labour. Br J Obstet Gynaecol 1982;89:149-54. (Level I)
159. Erkkola R, Kero P, Kanto J, Aaltonen L. Severe abuse of psychotropic drugs during pregnancy with good perinatal outcome. Ann Clin Res 1983;15:88-91. (Level III)
160. Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. Obstet Gynecol. 1985;66(suppl):34s-35s. (Level III)
161. Sanchis A, Rosique D, Catala J. Adverse effects of maternal lorazepam on neonates. DICP 1991;25:1137-8. (Level III)
162. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed) 1981;282:1106-8. (Level II-2)
163. Barry WS, St Clair S. Exposure to benzodiazepines in utero. Lancet 1987;1:1436-7. (Level III)
164. Bitnun S. Possible effect of chlordiazepoxide on the fetus. Can Med Assoc J 1969;100:351. (Level III)
165. Stirrat GM, Edington PT, Berry DJ. Transplacental passage of chlordiazepoxide [letter]. Br Med J 1974;2:729. (Level III)
166. Athinarayanan P, Pierog SH, Nigam SK, Glass L. Chloriazepoxide withdrawal in the neonate. Am J Obstet Gynecol 1976;124:212-3. (Level III)
167. Mazzi E. Possible neonatal diazepam withdrawal: a case report. Am J Obstet Gynecol 1977;129:586-7. (Level III)
168. Backes CR, Cordero L. Withdrawal symptoms in the neonate from presumptive intrauterine exposure to diazepam: report of case. J Am Osteopath Assoc 1980;79:584-5. (Level III)
169. Laegreid L, Olegard R, Wahlstrom J, Conradi N. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987;1:108-109. (Level III)
170. Gerhardsson M, Alfredsson L. In utero exposure to benzodiazepines [letter]. Lancet 1987:628. (Level III)
171. Winter RM. In-utero exposure to benzodiazepines [letter]. Lancet 1987;1:627. (Level III)
172. Hartz SC, Heinonen OP, Shapiro S, Siskind V, Slone D. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975;292:726-8. (Level II-2)
173. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-9;quiz 546. (Level III-3)
174. Goldberg HL, DiMascio A. Psychotropic drugs in pregnancy. In: Lipton MA, DiMascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York (NY): Raven Press; 1978. p.1047-55. (Level III)
175. Hill RM, Stern L. Drugs in pregnancy: effects on the fetus and newborn. Drugs 1979;17:182-97. (Level III)
176. Nurnberg HG, Prudic J. Guidelines for treatment of psychosis during pregnancy. Hosp Community Psychiatry 1984;35:67-71. (Level III)
177. Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969;9:224-7. (Level II-2)
178. Miklovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976;125:244-8. (Level II-2)
179. Moriarty AJ, Nance NR. Trifluoperazine and pregnancy [letter]. Can Med Assoc J 1963;88:375-6. (Level III)
180. Rawlings WJ. Use of medroxyprogesterone in the treatment of recurrent abortion. Med J Aust 1963;50:183-4. (Level III)
181. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977;15:57-64. (Level II-2)
182. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984;25:32-7. (Level II-2)
183. Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res Clin Exp 1965;7:785-9. (Level III)
184. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977;128:486-8. (Level II-2)
185. James ME. Neuroleptic malignant syndrome in pregnancy. Psychosomatics 1988;29:119-22. (Level III)
186. Collins KO, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. Am J Health Syst Pharm 2003;60:2253-5. (Level III)
187. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966;69:589-95. (Level III)
188. Scokel PW 3rd, Jones WN. Infant jaundice after phenothiazine drugs for labor: an enigma. Obstet Gynecol 1962;20:124-7. (Level II-2)
189. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980;97:308-10. (Level III)
190. Heinonen OP, Shapiro S, Slone D. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group; 1977. (Level III)
191. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J 1971;1:523-7. (Level III)
192. Hale TW. Medications in Mother's Milk. Amaraillo (TX): Pharmasoft Publishing, 2004. (Level III)
193. Stowe ZN, Owens MJ, Landry JC, Kilts CD, Ely T, Llewellyn A, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997;154:1255-60. (Level II-3)
194. Altshuler LL, Burt VK, McMullen M, Hendrick V. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995;56:243-5. (Level III)
195. Epperson CN, Anderson GM, McDougle CJ. Sertraline and breast-feeding. N Engl J Med 1997;336:1189-90. (Level III)
196. Kristensen JH, Ilett KF, Dusci LJ, Hackett LP, Yapp P, Wojnar-Horton RE, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998;45:453-7. (Level III)
197. Mammen O, Perel JM, Wheeler S. Antidepressants and breast-feeding. Am J Psychiatry 1997;154:1174-5. (Level III)
198. Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding motherinfant pairs. Am J Psychiatry 1998;155:690-2. (Level III)
199. Birnbaum CS, Cohen LS, Bailey JW, Grush LR, Robertson LM, Stowe ZN. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999;104(1):e11. (Level III)
200. Dodd S, Buist A, Norman TR. Antidepressants and breast-feeding: a review of the literature. Paediatr Drugs 2000;2:183-92. (Level III)
201. Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000;157:185-9. (Level II-3)
202. Epperson N, Czarkowski KA, Ward-O'Brien D, Weiss E, Gueorguieva R, Jatlow P, et al. Maternal sertraline treatment and serotonin transport in breast-feeding motheri-infant pairs. Am J Psychiatry 2001;158:1631-7. (Level II-3)
203. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatr 2001;179:163-6. (Level II-3)
204. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992;89:676-7. (Level III)
205. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993;32:1253-5. (Level III)
206. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996;36:42-7. (Level II-3)
207. Yoshida K, Kumar RC, Smith B, Craggs M. Psychotropic drugs in breast milk: no evidence for adverse effects on prepulse modulation of startle reflex or on cognitive level in infants. Dev Psychobiol 1998;32:249-56. (Level II-2)
208. Cohen LS, Heller V, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000;48:996-1000. (Level II-2)
209. Spigset O, Carleborg L, Norstrom A, Sandlund M. Paroxetine level in breast milk. J Clin Psychiatry 1996;57:39. (Level III)
210. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999;60:519-23. (Level III)
211. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. British Journal of Clinical Pharmacology 1991;31(2):209. (Level III)
212. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001;62:111-3. (Level III)
213. Jensen PN, Olesen OV, Bertelsen A, Linnet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997;19:236-9. (Level III)
214. Spigset O, Carieborg L, Ohman R, Norstrom A. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997;44:295-8. (Level III)
215. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry 2000;47:164-5. (Level III)
216. Stowe ZN, Hostetter AL, Owens MJ, Ritchie JC, Sternberg K, Cohen LS, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 2003;64:73-80. (Level III)
217. Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 1985;2:1124. (Level III)
218. Ilett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998;45:459-62. (Level III)
219. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of bupropion in breast milk. Ann Pharmacother 1993;27:431-3. (Level III)
220. Baab SW, Peindl KS, Piontek CM, Wisner KL. Serum bupropion levels in 2 breastfeeding mother-infant pairs. J Clin Psychiatry 2002;63:910-1. (Level III)
221. Weinstein MR, Goldfield M. Lithium carbonate treatment during pregnancy; report of a case. Dis Nerv Syst 1969;30:828-32. (Level III)
222. Fries H. Lithium in pregnancy. Lancet 1970;1:1233. (Level III)
223. Tunnessen WW Jr, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatr 1972;81:804-7. (Level III)
224. Schou M, Amdisen A. Lithium and pregnancy. 3.: lithium ingestion by children breast-fed by women on lithium treatment. BMJ 1973;2:138. (Level III)
225. Sykes PA, Quarrie J, Alexander FW. Lithium carbonate and breast-feeding [letter]. BMJ 1976;2:1299. (Level III)
226. Transfer of drugs and other chemicals into human milk. American Academy of Pediatrics Committee on Drugs. Pediatrics 2001;108:776-89. (Level III)
227. Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997;130:1001-3. (Level III)
228. Alexander FW. Sodium valproate and pregnancy. Arch Dis Child 1979;54:240-1. (Level III)
229. Dickinson RG, Harland RC, Lynn RK, Smith WB, Gerber N. Transmission of valproic acid (Depakene) across the placenta: half-life of the drug in mother and baby. J Pediatr 1979;94:832-5. (Level III)
230. Nau H, Rating D, Koch S, Hauser I, Helge H. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 1981;219:768-77. (Level II-3)
231. Bardy AH, Teramo K, Hiilesmaa VK. Apparent plasma clearances of phenytoin, phenobarbitone, primidone, and carbamazepine during pregnancy: results of the Prospective Helsinki Study. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D, editors. Epilepsy, pregnancy, and the child. New York (NY): Raven Press; 1982. p.141-5. (Level III-3)
232. von Unruh GE, Froescher W, Hoffmann F, Niesen M. Valproic acid in breast milk: how much is really there? Ther Drug Monit 1984;6:272-6. (Level III)
233. Tsuru N, Maeda T, Tsuruoka M. Three cases of delivery under sodium valproate - placental transfer, milk transfer and probable teratogenicity of sodium valproate. Jpn J Psychiatry Neurol 1988;42:89-96. (Level III)
234. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Clin Psychopharmacol 1998;18:167-9. (Level III)
235. Piontek CM, Baab S, Peindl KS, Wisner KL. Serum valproate levels in 6 breastfeeding mother-infant pairs. J Clin Psychiatry 2000;61:170-2. (Level III)
236. Bennett PN, editor. Drugs and human lactation. 2nd ed. New York (NY): Elsevier; 1996. (Level III)
237. Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002;36:644-7. (Level III)
238. Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990;150:136-8. (Level III)
239. Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant of an epileptic mother treated with carbamazepine during pregnancy and breastfeeding. Ann Pharmacother 1992;26:1563-5. (Level III)
240. Wretlind M. Excretion of oxazepam in breast milk. Eur J Clin Pharmacol 1987;33:209-10. (Level III)
241. Summerfield RJ, Nielsen MS. Excretion of lorazepam into breast milk. Br J Anaesth 1985;57:1042-3. (Level III)
242. Buist A, Norman TR, Dennerstein L. Breastfeeding and the use of psychotropic medication: a review. J Affect Disord 1990;19:197-206. (Level III)
243. Wesson DR, Camber S, Harkey M, Smith DE. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs 1985;17(1):55-56. (Level III)
244. Kris EB, Carmichael DM. Chlorpromazine maintenance therapy during pregnancy and confinement. Psychiatr Q 1957;31:690-5. (Level III)
245. Yoshida K, Smith B, Craggs M, Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med 1998;28:81-91. (Level II-2)